Identifying Multi-Hit Cancer Drivers Without Massive Parallelization: A CP, MIP, and Column Generation Framework
Organizations: Virginia Tech, Edward Via College of Osteopathic Medicine, USA
Abstract
Cancer is often driven by specific combinations of an estimated two to nine gene mutations, known as multi-hit combinations. Identifying these multi-hit combinations of gene mutations that drive cancer is critical for understanding carcinogenesis and designing targeted therapies. We formalize this challenge as the Multi-Hit Cancer Driver Set Cover Problem (MHCDSCP), optimizing the selection of gene combinations to maximize tumor coverage while strictly minimizing normal sample misclassification. While existing approaches rely on exhaustive enumeration and massive parallelization, we introduce fast heuristics based on constraint programming and mixed integer programming formulations. Evaluated on real-world cancer genomics data, our framework matches state-of-the-art supercomputing methods using a single commodity CPU in under a minute. We also propose a price-and-branch heuristic which, by solving the root node to optimality, provides the first provably optimal solutions for over half of the benchmark instances, thereby verifying the near-optimality of our fast heuristics. These findings demonstrate that on real-world problem instances, the MHCDSCP is far less computationally demanding than previously believed, providing an accessible baseline that enables the exploration of previously intractable multi-hit modeling assumptions.
Figures & tables
| dataset | cancer type | #hits | #genes | #samples | #mutations |
| \multirow 2*A | BRCA | 3, 2–3, 6–7 | 19,411 | 1242 | 837,207 |
| PRAD | 6–7, 7 | 17,274 | 752 | 476,115 | |
| \multirow 16*B | BLCA-B | 4, 6–7, 7 | 19,408 | 705 | 503,615 |
| BRCA-B | 3, 2–3, 6–7 | 20,728 | 1260 | 969,254 | |
| CESC-B | 5, 6–7 | 20,073 | 613 | 430,358 | |
| COAD-B | 3, 4, 5, 6 | 20,940 | 730 | 737,797 |
| cancer type | hit range | solution | training performance | test performance | |||||||||||
| #comb | obj | solver time (s) | MCC | spec | sens | F1 | MCC | spec | sens | F1 | |||||
| \multirow 3*BRCA | 2-3 | 10 | 677 | 1200.0 | 0.984 | 0.996 | 0.993 | 0.996 | 0.872 | 0.940 | 0.952 | 0.964 | |||
| 3 | 10 | 672 | 1200.0 | 0.973 | 0.984 | 0.991 | 0.993 | 0.887 | 0.940 | 0.961 | 0.969 | ||||
| 6-7 | 10 | 505 | 1200.0 | 0.625 | 0.915 | 0.779 | 0.861 | 0.558 | 0.855 | 0.763 | 0.841 | ||||
| \multirow 2*PRAD | 6-7 | 10 | 239 | 1200.0 | 0.752 | 0.972 | 0.782 | 0.867 | 0.596 | 0.952 | 0.629 | 0.754 | |||
| 7 | 10 | 211 | 1200.0 | 0.667 | 0.952 | 0.712 | 0.814 | 0.525 | 0.952 | 0.543 | 0.687 | ||||
| cancer type | hit range | solution | training performance | test performance | |||||||||||
| #comb | obj | solver time (s) | MCC | spec | sens | F1 | MCC | spec | sens | F1 | |||||
| \multirow 3*BRCA | 2-3 | 10 | 678 | 30.0 | 0.986 | 1.000 | 0.993 | 0.996 | 0.878 | 0.928 | 0.961 | 0.967 | |||
| 3 | 10 | 677 | 30.0 | 0.984 | 1.000 | 0.991 | 0.996 | 0.864 | 0.928 | 0.952 | 0.962 | ||||
| 6-7 | 10 | 517 | 30.0 | 0.663 | 0.968 | 0.773 | 0.866 | 0.551 | 0.880 | 0.737 | 0.828 | ||||
| \multirow 2*PRAD | 6-7 | 10 | 244 | 17.3 | 0.775 | 0.988 | 0.788 | 0.877 | 0.642 | 0.964 | 0.667 | 0.787 | |||
| 7 | 10 | 216 | 22.5 | 0.692 | 0.988 | 0.693 | 0.814 | 0.564 | 0.952 | 0.590 | 0.725 | ||||
| cancer type | hit range | solution | training performance | test performance | ||||||||||||
| #comb | obj | bound | solver time (s) | MCC | spec | sens | F1 | MCC | spec | sens | F1 | |||||
| \multirow 3*BRCA | 2-3 | 10 | 677 | 683 | 51.8 | 0.984 | 1.000 | 0.991 | 0.996 | 0.896 | 0.952 | 0.961 | 0.971 | |||
| 3 | 10 | 678 | 683 | 56.3 | 0.986 | 0.996 | 0.994 | 0.996 | 0.843 | 0.880 | 0.961 | 0.958 | ||||
| 6-7 | 10 | 637 | - | 300.0 | 0.891 | 0.972 | 0.949 | 0.969 | 0.796 | 0.952 | 0.895 | 0.936 | ||||
| \multirow 2*PRAD | 6-7 | 10 | 280 | - | 300.0 | 0.876 | 0.984 | 0.899 | 0.940 | 0.639 | 0.916 | 0.724 | 0.809 | |||
| 7 | 10 | 254 | - | 300.0 | 0.783 | 0.931 | 0.858 | 0.897 | 0.488 | 0.855 | 0.629 | 0.721 | ||||
| cancer type | hit range | BiGPICC on Dataset A (results reported from [ 28 ] ) | GR-MIP on Dataset A | ||||||||||
| #comb | MCC | spec | sens | F1 | #comb | MCC | spec | sens | F1 | ||||
| \multirow 3*BRCA | 2-3 | 5 | 0.900 | 0.892 | 0.987 | 0.974 | 10 | 0.878 | 0.928 | 0.961 | 0.967 | ||
| 3 | 9 | 0.900 | 0.892 | 0.987 | 0.974 | 10 | 0.864 | 0.928 | 0.952 | 0.962 | |||
| 6-7 | 34 | 0.749 | 0.916 | 0.882 | 0.922 | 10 | 0.551 | 0.880 | 0.737 | 0.828 | |||
| \multirow 2*PRAD | 6-7 | 45 | 0.436 | 0.831 | 0.600 | 0.692 | 10 | 0.642 | 0.964 | 0.667 | 0.787 | ||
| 7 | 62 | 0.487 | 0.928 | 0.533 | 0.671 | 10 | 0.564 | 0.952 | 0.590 | 0.725 | |||
| cancer type | hit range | GR-MIP on Dataset B | Price-and-Branch on Dataset B | ||||||||||||
| obj | gap | total time (s) | #comb | MCC | spec | sens | F1 | obj | bound | gap | total time (s) | ||||
| \multirow 3*BLCA-B | 4 | 280 | 0.00 | 18.9 | 10 | 0.932 | 0.952 | 0.979 | 0.968 | 280 | 280 | 0.00 | 42.7 | ||
| 6-7 | 280 | 0.00 | 39.0 | 10 | 0.831 | 0.988 | 0.840 | 0.908 | 279 | 280 | 0.36 | 100.9 | |||
| 7 | 270 | - | 39.4 | 10 | 0.863 | 1.000 | 0.862 | 0.926 | 276 | - | - | 311.7 | |||
| \multirow 3*BRCA-B | 2-3 | 697 | 0.00 | 52.4 | 9 | 0.984 | 0.988 | 0.996 | 0.996 | 697 | 697 | 0.00 | 46.0 | ||
| 3 | 697 | 0.00 | 47.2 | 7 | 0.967 | 0.964 | 0.996 | 0.991 | 697 | 697 | 0.00 | 49.8 | |||
Appendix figures & tables1 asset
Supplementary material from the paper’s appendix.
Appendix
| cancer type | hit range | full MIP | reduced MIP + full MIP | VNS + reduced MIP + full MIP | ||||||||||||
| obj | #iter | MP time (s) | PP time (s) | obj | #iter | MP time (s) | PP time (s) | obj | #iter | MP time (s) | PP time (s) | |||||
| \multirow 3*BRCA | 2-3 | 665 | 8 | 0.0 | 300.0 | 669 | 15 | 0.0 | 300.0 | 677 | 62 | 0.1 | 51.5 | |||
| 3 | 651 | 8 | 0.0 | 300.0 | 661 | 24 | 0.0 | 300.0 | 678 | 113 | 0.1 | 56.1 | ||||
| 6-7 | 590 | 10 | 0.0 | 300.0 | 615 | 87 | 0.1 | 299.9 | 637 | 115 | 0.2 | 299.8 | ||||
| \multirow 2*PRAD | 6-7 | 264 | 17 | 0.0 | 300.0 | 281 | 177 | 0.2 | 299.8 | 280 | 212 | 0.3 | 299.7 | |||
| 7 | 235 | 16 | 0.0 | 300.0 | 257 | 217 | 0.2 | 299.8 | 254 | 134 | 0.1 | 299.9 | ||||
Cancer Genomics
Cancer genomics uses molecular data to understand tumor biology, identify biomarkers, and guide diagnosis, prognosis, and treatment.
See all 34 papers